Thus, β-cell STARD10 may be a useful therapeutic target in some forms of type 2 diabetes, particularly in risk allele carriers who may benefit from a tailored, pharmacogenetic approach. The gene discussed is STARD10; the disease is type 2 diabetes mellitus.